Global Ovarian Cancer Drugs Market by Therapeutics Class (Angiogenesis Inhibitors, PARP Inhibitors, PD-L1 Inhibitors), Modality (Chemotherapy, Hormonal Therapy, Targeted Therapy), Drugs - Forecast 2024-2030- Product Image

Sale

Global Ovarian Cancer Drugs Market by Therapeutics Class (Angiogenesis Inhibitors, PARP Inhibitors, PD-L1 Inhibitors), Modality (Chemotherapy, Hormonal Therapy, Targeted Therapy), Drugs - Forecast 2024-2030

Report
189 Pages
March 2024
Region: Global
360iResearch™
ID: 4896711

UP TO €846EUR$875USD£717GBP OFF until Dec 31^st 2024

The Ovarian Cancer Drugs Market size was estimated at USD 3.95 billion in 2023, USD 4.49 billion in 2024, and is expected to grow at a CAGR of 13.75% to reach USD 9.73 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Ovarian Cancer Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Ovarian Cancer Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Ovarian Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Ltd., Allergan PLC, AstraZeneca PLC, Boehringer Ingelheim, Cipla Ltd., Clovis Oncology, F. Hoffmann-La Roche AG, Fresenius Kabi India Pvt. Ltd., GlaxoSmithKline PLC, Merck & Co., Inc., Mylan Pharmaceuticals Pvt. Ltd., Pfizer, Inc., Sanofi S.A., and Syndax Pharmaceuticals, Inc.

Market Segmentation & Coverage

This research report categorizes the Ovarian Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Therapeutics Class
- Angiogenesis Inhibitors
- PARP Inhibitors
- PD-L1 Inhibitors
Modality
- Chemotherapy
- Hormonal Therapy
- Targeted Therapy
Drugs
- Avastin
- Carboplatin
- Doxil
- Lynparza
- Yondelis

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Ovarian Cancer Drugs Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Ovarian Cancer Drugs Market?
What are the technology trends and regulatory frameworks in the Ovarian Cancer Drugs Market?
What is the market share of the leading vendors in the Ovarian Cancer Drugs Market?
Which modes and strategic moves are suitable for entering the Ovarian Cancer Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Ovarian Cancer Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of ovarian cancer around the globe
5.1.1.2. Increasing geriatric population of women around the world
5.1.1.3. Adoption of novel drugs and strong developmental pipeline
5.1.2. Restraints
5.1.2.1. Adverse impact of cancer drugs on the human body
5.1.3. Opportunities
5.1.3.1. Rising funding in the healthcare industry by the government in developing countries
5.1.3.2. Developments in ovarian cancer drugs in emerging economies
5.1.4. Challenges
5.1.4.1. Cost associated with the treatment of ovarian cancer is high
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Ovarian Cancer Drugs Market, by Therapeutics Class

6.1. Introduction
6.2. Angiogenesis Inhibitors
6.3. PARP Inhibitors
6.4. PD-L1 Inhibitors

7. Ovarian Cancer Drugs Market, by Modality

7.1. Introduction
7.2. Chemotherapy
7.3. Hormonal Therapy
7.4. Targeted Therapy

8. Ovarian Cancer Drugs Market, by Drugs

8.1. Introduction
8.2. Avastin
8.3. Carboplatin
8.4. Doxil
8.5. Lynparza
8.6. Yondelis

9. Americas Ovarian Cancer Drugs Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Ovarian Cancer Drugs Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Ovarian Cancer Drugs Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. Alkem Laboratories Ltd.
13.1.3. Allergan PLC
13.1.4. AstraZeneca PLC
13.1.5. Boehringer Ingelheim
13.1.6. Cipla Ltd.
13.1.7. Clovis Oncology
13.1.8. F. Hoffmann-La Roche AG
13.1.9. Fresenius Kabi India Pvt. Ltd.
13.1.10. GlaxoSmithKline PLC
13.1.11. Merck & Co., Inc.
13.1.12. Mylan Pharmaceuticals Pvt. Ltd.
13.1.13. Pfizer, Inc.
13.1.14. Sanofi S.A.
13.1.15. Syndax Pharmaceuticals, Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. OVARIAN CANCER DRUGS MARKET RESEARCH PROCESS
FIGURE 2. OVARIAN CANCER DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. OVARIAN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. OVARIAN CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. OVARIAN CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. OVARIAN CANCER DRUGS MARKET DYNAMICS
FIGURE 7. OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2023 VS 2030 (%)
FIGURE 8. OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2023 VS 2030 (%)
FIGURE 10. OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
FIGURE 12. OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. OVARIAN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. OVARIAN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. OVARIAN CANCER DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. OVARIAN CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 6. OVARIAN CANCER DRUGS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. OVARIAN CANCER DRUGS MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. OVARIAN CANCER DRUGS MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 10. OVARIAN CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. OVARIAN CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. OVARIAN CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 14. OVARIAN CANCER DRUGS MARKET SIZE, BY AVASTIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. OVARIAN CANCER DRUGS MARKET SIZE, BY CARBOPLATIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. OVARIAN CANCER DRUGS MARKET SIZE, BY DOXIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. OVARIAN CANCER DRUGS MARKET SIZE, BY LYNPARZA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. OVARIAN CANCER DRUGS MARKET SIZE, BY YONDELIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 28. BRAZIL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 29. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 30. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 31. CANADA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 32. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 33. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 34. MEXICO OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 38. UNITED STATES OVARIAN CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 42. ASIA-PACIFIC OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 45. AUSTRALIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 46. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 47. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 48. CHINA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 49. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 50. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 51. INDIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 54. INDONESIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 55. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 56. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 57. JAPAN OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 60. MALAYSIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 63. PHILIPPINES OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 66. SINGAPORE OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 69. SOUTH KOREA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 72. TAIWAN OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 73. THAILAND OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 74. THAILAND OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 75. THAILAND OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 78. VIETNAM OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. DENMARK OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 84. DENMARK OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 85. DENMARK OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 86. EGYPT OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 87. EGYPT OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 88. EGYPT OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 89. FINLAND OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 90. FINLAND OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 91. FINLAND OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 92. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 93. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 94. FRANCE OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 95. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 96. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 97. GERMANY OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 100. ISRAEL OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 101. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 102. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 103. ITALY OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 106. NETHERLANDS OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 109. NIGERIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 110. NORWAY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 111. NORWAY OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 112. NORWAY OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 113. POLAND OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 114. POLAND OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 115. POLAND OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 116. QATAR OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 117. QATAR OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 118. QATAR OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 121. RUSSIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 124. SAUDI ARABIA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 127. SOUTH AFRICA OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 128. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 129. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 130. SPAIN OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 133. SWEDEN OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 136. SWITZERLAND OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 137. TURKEY OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 138. TURKEY OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 139. TURKEY OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 142. UNITED ARAB EMIRATES OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY THERAPEUTICS CLASS, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM OVARIAN CANCER DRUGS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
TABLE 146. OVARIAN CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 147. OVARIAN CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 148. OVARIAN CANCER DRUGS MARKET LICENSE & PRICING

Companies Mentioned

Abbott Laboratories
Alkem Laboratories Ltd.
Allergan PLC
AstraZeneca PLC
Boehringer Ingelheim
Cipla Ltd.
Clovis Oncology
F. Hoffmann-La Roche AG
Fresenius Kabi India Pvt. Ltd.
GlaxoSmithKline PLC
Merck & Co., Inc.
Mylan Pharmaceuticals Pvt. Ltd.
Pfizer, Inc.
Sanofi S.A.
Syndax Pharmaceuticals, Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	189
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 4.49 Billion
Forecasted Market Value ( USD ) by 2030	$ 9.73 Billion
Compound Annual Growth Rate	13.7%
Regions Covered	Global
No. of Companies Mentioned	15

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3263EUR$3,374USD£2,763GBP €3625EUR$3,749USD£3,070GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4133EUR$4,274USD£3,500GBP €4593EUR$4,749USD£3,889GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5004EUR$5,174USD£4,238GBP €5560EUR$5,749USD£4,708GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5874EUR$6,074USD£4,975GBP €6527EUR$6,749USD£5,527GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7615EUR$7,874USD£6,449GBP €8461EUR$8,749USD£7,165GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

United States Ovarian Cancer Therapeutics Market, Competition, Forecast & Opportunities, 2028

Ovarian Cancer Therapeutics - Global Strategic Business Report

Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors), By Treatment, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Global Ovarian Cancer Diagnostics And Therapeutics Market Report and Forecast 2024-2032

RUBRACA Market Size, Forecast, and Drug Insight - 2032

About the Ovarian Cancer Drugs Market